A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials with SGLT2 inhibitors, however, revealed a 39% higher risk of renal cancers with SGLT2 inhibitors compared with a placebo [54], though the overall cancer risk was not increased in the SGLT2 inhibitor group [54]. This evidence concerns the gene SLC5A2 and cancer.